Drugs /

mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201

Back to Drugs List

Overview

NCI Definition [1]:
Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T-lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.

Clinical Trials

View Clinical Trials for mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201

Mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201, 1 is phase 1 (0 open).

HLA-A*24:02 Positive and MAGEA4 Expression are the most frequent biomarker inclusion criteria for mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 clinical trials.

Malignant solid tumor is the most common disease being investigated in mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Mage-A4-Specific Tcr Gene-Transduced Autologous T Lymphocytes Tbi-1201
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tbi-1201, mage-a4-specific tcr gene-transduced t lymphocytes tbi-1201
Drug Target(s) [2]:
MAGEA4
NCIT ID [1]:
C114978

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.